Plasma Fractionation Market - By Product, By Method, By Application, By End Use - Global Forecast, 2025 - 2034

Plasma Fractionation Market Size

The global plasma fractionation market was estimated at USD 33.7 billion in 2024. The market is expected to grow from USD 36.7 billion in 2025 to USD 65.3 billion in 2034, growing at a CAGR of 6.6%. This high growth is attributed to several factors including rise in adoption of immunoglobulins in various therapeutic applications, growing demand for advanced treatment options, and technological advancements in plasma fractionation process among other contributing factors.

The industrial process used to separate plasma proteins from blood is known as plasma fractionation. Major players operating in the industry includes CSL, Grifols, Octapharma, Takeda, and Kedrion Biopharma among other key companies. Rise in neurological diseases, immunodeficiency disorders and growing patient burden due to autoimmune diseases is resulting in increasing demand for immunoglobulins.
 

The market witnessed healthy growth from USD 24.3 billion in 2021 to USD 30.6 billion in 2023, and is expected to register healthy growth with a CAGR of 12.1% during the forecast period. This growth was primarily driven by increased demand for advanced treatment options. Human blood plasma contains essential proteins that strengthen the immune system and help fight infections and inflammation. These properties make plasma-derived biologics valuable in treating rare, chronic, and genetic diseases such as hemophilia. The key proteins in these treatments include immunoglobulins, coagulation factors, fibrin sealants, and albumin. For instance, albumin helps treat serious injuries, while fibrinogen-based products assist in blood clotting.
 

Additionally, increasing investments in expanding infrastructure and research and development activities by leading industry players to consolidate their industry position is fueling the market growth. For instance, in June 2025, Octapharma, a key industry participant recently announced that it expanded its manufacturing facility output by around 50 percent at the Vienna, Austria location to cater the increasing global demand. The expansion also enhanced company's packaging and logistics capacities to support the increased product output. Thus, significant investment in facility expansion by market players is spurring the industry growth.
 

Further, the growing patient population suffering from range of medical conditions including genetic disorders, bleeding disorders, primary immunodeficiency diseases, etc. Patients with primary immunodeficiency generally require regular infusions or injections throughout their lives, ranging from twice a week to once a month. Further, increasing diagnosis rate for various disorders including the genetic disease is leading to increased demand for therapies and plasma-derived medicinal products. For instance, as per the data reported in The World Health Organization (WHO) report, around 80 million people in the world are expected to have genetic diseases. Thus, the growing awareness, demand and need to develop medicines for such indications is boosting the industry growth.
 

The industrial process used to separate plasma proteins from donated blood is known as plasma fractionation. These separated plasma proteins including albumin, coagulation factors, etc. are used in various therapeutic applications.
 

Plasma Fractionation Market Trends

Supportive government strategies for self-sufficiency in manufacturing blood plasma and products derived from it, advancements in plasma fractionation and considerable research and development developments are among the key trends shaping the market growth.
 

• Various countries around the world such as U.S., China, Germany, and Australia among others has a well-established manufacturing capacity for plasma fractionation. Due to growing demand for blood plasma across various therapeutic applications, several countries are supporting the development of new facilities with an aim to achieve self-sufficiency and reduce the import dependency.
   
• For instance, in January 2025, Vietnam started the construction of its first plasma-based biopharmaceutical production plant, located in industrial park of Ho Chi Minh City. The facility is expected to be operational by February 2026 with a capacity of around 0.6 million liters of plasma annually.
   
• Additionally, in order to boost the regional self-sufficiency, in 2021, the UK government lifted its ban on the use of domestic blood plasma for clinical applications that were put 20 years ago due to the fear of mad cow disease (or bovine spongiform encephalopathy). This ban resulted in significant increase in blood plasma collection in the country, thereby spurring the industry growth.
   
• Further, growing research and development activities for plasma-derived therapies is a key trend leading to development of various therapeutic applications for wide range of medical conditions. Hence, afore mentioned variables are anticipated to fuel the market growth over the analysis period.
   

Plasma Fractionation Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The global plasma fractionation market witnessed growth from USD 24.3 billion in 2021 to USD 30.6 billion in 2023 and is expected to record a growth with a CAGR of 12.1% over the forecast period.
 

Based on product, the plasma fractionation market is segmented into immunoglobulins, coagulation factors, albumin, protease inhibitors and other plasma products. The immunoglobulins segment accounted for 46.8% of the market in 2024 owing to increasing demand for plasma-derived therapies and growing prevalence of various diseases including respiratory and genetic disorders. The segment is expected to exceed USD 31.5 billion by 2034, growing at a CAGR of 7% during the forecast period. In addition, coagulation factor segment is expected to witness growth at 6.7% CAGR over the forecast period.
 

• The immunoglobulins segment is experiencing growth due to the rising number of neurological and immunological diseases, alongside increased off-label use of immunoglobulins, especially IVIg. For instance, according to the data released by The Lancet Neurology study in 2021, over 3 billion patients were suffering from some kind of neurological disorders in the world. This high disease burden needs proper medication for different brain related diseases, thus propelling the industry growth.
•  
• Additionally, as doctors expand the use of immunoglobulins to treat various conditions such as immune thrombocytopenic purpura, Guillain-Barré syndrome, and Kawasaki syndrome, the segment continues to witness healthy growth throughout the analysis period.
   
• Further, the coagulation factor segment accounted for around 23.6% share in 2024 and is anticipated to record robust growth over the forecast period. The rise in bleeding disorders such as hemophilia and other conditions that need managing bleeding during surgery are projected to spur the industry demand.
   
• Moreover, albumin segment was valued at USD 5.5 billion in 2024 owing to its widespread adoption in range of medical treatments, research activities, and drug delivery systems among other factors.
   

Based on method, the plasma fractionation market is segmented into cold ethanol fractionation, chromatography, centrifugation, and other methods. The cold ethanol fractionation segment accounted for the highest market share of 47.9% in 2024 due to the key role it plays in the industrial scale plasma fractionation in manufacturing facilities.
 

• The cold ethanol fractionation technique offers high purity and yield of specific plasma proteins. The method maintains a proper balance between safety and efficient extraction during the process.
   
• In addition, it is among the most widely adopted method owing to its operational affordability, proven technology and better purity standard. It is among the preferred method used to isolate albumin and immunoglobulins among other protein plasma as it has the ability to separate multiple proteins simultaneously.
   
• However, the chromatography segment is anticipated to record fastest growth with a CAGR of 7% over the forecast period. Demand for chromatography is rapidly rising owing to its higher purity, specificity, and scalability. Chromatography is increasingly favored in advanced facilities, particularly for niche and high-value protein isolation, driving a shift toward hybrid processing approaches.
   
• Moreover, variables such as increasing integration of automation in the facility, better virus removal capability and consistent advancements in process refinement are expected to fuel the industry growth.
   

Based on application, the plasma fractionation market is segmented into immunology, neurology, hematology, pulmonology, oncology, and other applications. The immunology segment accounted for the highest market share of 38.9% in 2024 owing to growing prevalence of different immunology diseases such as autoimmune disease, allergies, asthma, etc.
 

• Variations in genetics, infections in the immune system among other factors in the patient may result in autoimmune diseases. Currently, there are more than 100 types of autoimmune diseases listed that includes systemic lupus erythematosus (SLE), Sjögren’s syndrome, type 1 diabetes and rheumatoid arthritis among others.
   
• For instance, according to the data reported by Sjögren’s Foundation, Inc., around 50 million U.S. citizens are suffering from some kind of autoimmune disease, and the estimates suggest a considerable rise in the target population. In addition, various epidemiological studies conducted across the world highlights a notable rise in different autoimmune indications such as rheumatological diseases.
   
• Further, neurology segment accounted for second-largest share of around 26.2% in 2024. Increasing prevalence of different brain related disorders is a key factor driving the demand for plasma-derived medications for these conditions.
   
• Moreover, owing to significant rise in number of people suffering from various respiratory illnesses including asthma, COPD, etc. the pulmonology segment is projected to witness healthy growth during the forecast timeline.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the plasma fractionation market is segmented into hospitals and clinics, clinical research laboratories, and other end users. The hospitals and clinics segment accounted for the highest market share of 61.8% in 2024 owing to high patient footfall in these settings, availability of treatment at affordable cost and favorable reimbursement schemes.
 

• Hospitals and clinics remain at the forefront of the plasma fractionation market, serving as the largest end-use segment. The segment dominance is due to their ability to handle high patient volumes, provide immediate treatment access, and integrate plasma-derived therapies into daily patient care.
   
• These healthcare facilities act as key centers where patients receive essential plasma products such as immunoglobulins, albumin, and coagulation factors. These treatments help people manage conditions such as primary immunodeficiency, bleeding complications, etc.
   
• Further, well-trained healthcare professionals, supportive reimbursement coverage, and modern healthcare facilities strengthen the segment's position. In developing countries, both public and private hospitals are witnessing more patients seeking plasma-based treatments as healthcare becomes more accessible and rise in awareness.
   
• On the other hand, clinical research laboratories segment held the second-largest share at 30.7% in 2024. These labs focus on improving plasma derived therapy products, making production processes more efficient, and developing personalized treatments. Their work in early testing and development ensures new treatments are both innovative and safe for patients.
   

Looking for region specific data?

Download Free PDF

North America dominated the global plasma fractionation market with the leading market share of 33.1% in 2024.
 

• The U.S. plasma fractionation market was valued at 7.8 billion and USD 8.6 billion in 2021 and 2022, respectively. In 2024 the market size reached USD 10.4 billion from USD 9.5 billion in 2023. Presence of leading global market players, growing demand for plasma-derived products and increase in prevalence of different disorders are expected to support the market growth.
   
• The U.S. leads the plasma fractionation market owing to its well-developed healthcare system, rise in awareness for different plasma-based treatments, and widespread plasma donation centers. Doctors frequently prescribe immunoglobulins to help patients with autoimmune and neurological conditions and use coagulation factors to treat people with hemophilia.
   
• As more American citizens develop long-term health conditions, the need for albumin and other plasma proteins continues to record increased demand. Patients can access these treatments through various healthcare settings, including hospitals, specialty clinics, and at-home infusion services throughout the country.
   
• Further, ongoing innovation and expanding investments further support strong long-term demand within the country. For instance, in June 2024, Takeda Pharmaceutical announced the expansion of its Los Angeles based-plasma-derived therapies manufacturing capacity. The new facility is being designed with an annual capacity of 2 million liters of plasma fractionation. Thus, such developments in the country are expected to contribute to overall market growth.
   

Europe plasma fractionation market accounted for USD 10.5 billion in 2024.
 

• The European plasma fractionation market continues to grow as high geriatric population leads to more people developing immunodeficiency and bleeding disorders, and healthcare professional explore new therapeutic applications to use plasma-derived products. Countries such as Germany, France, UK, and Spain have a significant demand for consumption, due to their well-developed healthcare systems and widespread use of plasma proteins such as coagulation factors.
   
• European governments are taking steps to become self-sufficient in plasma sourcing and fractionation, focusing on reducing their reliance on imports. In March 2024, CSL announced the launch of a new plasma fractionation facility in Marburg, Germany. The company invested USD 470 million in developing the new facility.
   
• Further, as countries invest more in local facilities for collecting and processing plasma, they are better equipped to meet the growing needs of patients across Europe, thereby supporting the industry growth.
   

Asia Pacific plasma fractionation market is anticipated to witness high growth with a CAGR of 8.5% over the analysis timeframe.
 

• The Asia Pacific region is experiencing significant growth in plasma fractionation demand. This growth stems from expanding healthcare infrastructure, greater awareness of plasma-derived therapies, and an increasing number of patients opting for immunological and genetic testing.
   
• Major countries in the region, including China, India, Australia, and South Korea, are taking steps to strengthen their domestic plasma collection networks and manufacturing capabilities to reduce their dependence on imports. For example, in December 2022, CSL inaugurated a high-capacity plasma fractionation facility in Broadmeadows, Australia. The company invested USD 900 million in the new facility and has expanded its capacity to over 9 million liters annually.
   
• Plasma-derived medicinal products (PDMPs) are used to treat a variety of congenital and acquired diseases. Through government initiatives to expand health coverage and partnerships between public and private sectors, more patients now have access to plasma-based treatments. The above listed factors have promoted Asia Pacific as a key player in meeting global plasma requirements.
   

Latin America plasma fractionation market is expected to witness high growth over the forecast period.
 

• Latin America is experiencing a steady rise in plasma fractionation demand as more people suffer from bleeding disorders, liver diseases, and autoimmune conditions in the region. Brazil, Mexico, and Argentina are taking the lead in this growth, with supportive healthcare reforms making biologic therapies more accessible to patients.
   
• Public health institutions and private healthcare providers are now using more immunoglobulins and albumin to treat patients, especially in neurological and critical care settings.
   
• As the region improves its ability to diagnose diseases and treat patients, more healthcare facilities are adopting plasma-derived therapies. This increased awareness of treatment options and growing patient needs has positioned Latin America as an important market for plasma fractionation.
   

Plasma Fractionation Market Share

Leading companies such as CSL, Grifols, Octapharma, Takeda, and Kedrion Biopharma together hold around 80% of the market share in the consolidated global plasma fractionation market. These players keep their dominance in the industry by having well-established manufacturing capabilities for all types of plasma proteins, collaboration with major pharma companies globally, worldwide expansion, and consistent innovation.
 

Key players in the plasma fractionation market continue to focus on expanding their plasma collection capacity, improving manufacturing efficiency, and broadening their product portfolios. These companies invest in advanced fractionation technologies such as chromatography to achieve better yield and purity of plasma-derived proteins. They are also expanding their presence in Asia Pacific and Latin America to better serve local demand and build more resilient supply chains.
 

In addition, focus of local players investing in setting-up new facilities in their respective countries is another key factor supporting the market growth. Many industry players are working closely with local governments, building partnerships to ensure self-sufficiency and help meet evolving regulatory requirements.
 

Plasma Fractionation Market Companies

Few of the prominent players operating in the plasma fractionation industry include:

• LFB Group
• CSL
• GC Biopharma
• Grifols
• Intas Pharmaceuticals
• Japan Blood Products Organization (JB)
• Kamada Pharmaceuticals
• Kedrion Biopharma
• Octapharma
• Prothya Biosolutions
• SK Plasma
• Taibang Biologic Group
• Takeda
• VIRCHOW BIOTECH PRIVATE LIMITED
   
• CSL

CSL has established itself as a prominent player in the plasma fractionation industry with distribution spanning in more than 40 countries worldwide. Consistent research and development spending has enabled the company to emerge as a key competitor in the market.
 

• Grifols

Grifols focuses on product innovation and research for several products to fulfill demand for rare disease therapeutics. To expand its industry position, it is involved in developing, manufacturing and in the distribution of plasma-derived products.
 

• Takeda

Takeda has a significant market presence in the plasma fractionation industry. The company focuses on expanding its industry reach and production output with considerable investment in coming years. Company operates over 80 plasma collection facilities in the U.S. and Australia. Company is also involved in collaboration with other key industry players to cement its market position.
 

• Octapharma

Octapharma is engaged in research to improve its existing products and to discover novel therapeutic applications for different products made from human blood plasma. The company focuses on both organic and inorganic growth strategies such as collaborating with several industry players, product launches and geographical expansion.
 

Plasma Fractionation Industry News:

• In July 2025, Grifols announced that it will open new manufacturing facility in Barcelona, Spain with a target of doubling its current European capacity. The new facility is expected to go functional in 2030. This development is expected to expand company's manufacturing output in the region, supporting the global targets.
   
• In September 2024, Australia-based biotechnology firm CSL Limited announced that it has signed an agreement with Chengdu Rongsheng Pharmaceutical to sell its Wuhan Zhong Yuan Rui De Biologicals Products (Ruide) plasma collection and fractionation operations in China. This development may affect company's sales prospects in China in the coming years.
   
• In April 2022, Grifols completed the acquisition of Biotest. The acquisition by Grifols include 100% of the share of Tiancheng (Germany) Pharmaceutical Holdings AG which hold around 90% of the shares of Biotest. Thus, this acquisition enables the company to further consolidate its industry position.
   

The plasma fractionation market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Immunoglobulins
  • Intravenous immunoglobulins
  • Subcutaneous immunoglobulins
  • Other immunoglobulins
• Coagulation factors
  • Factor VIII
  • Factor IX
  • Prothrombin complex concentrates
  • VON WILLEBRAND factor
  • Fibrinogen concentrates
  • Other coagulation factor concentrates
• Albumin
• Protease inhibitors
• Other plasma products

Market, By Method

• Cold ethanol fractionation
• Chromatography
• Centrifugation
• Other methods

Market, By Application

• Immunology
• Neurology
• Hematology
• Pulmonology
• Oncology
• Other applications

Market, By End Use

• Hospitals and clinics
• Clinical research laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE